About Gaudium IVF and Women Health Limited
Gaudium IVF and Women Health Limited was incorporated in March 2015 and is engaged in providing assisted reproductive technology (ART) and fertility treatments across India. The company focuses on advanced In Vitro Fertilization (IVF) services and has expanded its presence in multiple states through a hub-and-spoke operating model. Currently, the company operates more than 30 locations, including 7 hub centres and 28 spoke centres. It has also entered into a strategic alliance with infertility experts to spread awareness about fertility and reproductive health treatments. Gaudium IVF serves both domestic and international patients from countries such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The company has centres in major cities like Delhi, Mumbai, Bangalore, Ludhiana, Srinagar, and Patna, which helps it cover key urban markets in India. The company offers a wide range of fertility and women’s health services such as IVF, ICSI, IUI, ovulation induction, PCOS and endometriosis treatment, and high-risk pregnancy care. It also provides advanced male infertility treatments, including sperm retrieval procedures.
Why To Invest in Gaudium IVF and Women Health Limited
Growing Fertility Industry : The demand for fertility and IVF treatments is increasing in India due to lifestyle changes, delayed pregnancies, and rising awareness about reproductive health.
Strong Financial Performance : The company has shown consistent growth in revenue and profitability. It reported total income of Rs. 70.96 crore and profit after tax of Rs. 19.13 crore in FY 2025, indicating strong margins and operational efficiency.
Asset-Light Business Model : The hub-and-spoke model allows the company to expand rapidly with lower capital investment and better scalability.
Expansion Plans : The company plans to use IPO funds to open new IVF centres, which can increase market reach and future revenue.
Experienced Promoters and Team : The company is led by experienced doctors and fertility specialists, which strengthens its brand and patient trust.
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
Explore Other Products
